Apogee’s Phase 2b Eczema Data Matches Leading Biologics, Backed by $1.3 B Funding
APGE•Apogee will present at investor conferences on June 3 and June 10, with live webcasts available on its website. Phase 2b data for zumilokibart showed efficacy matching leading biologics with 2–4 doses per year and is backed by up to $1.3 billion in Blackstone funding to eliminate near-term dilution risk.
1. Upcoming Investor Conferences
Apogee’s management will host fireside chats at the Jefferies Global Healthcare Conference on June 3 at 11:40 a.m. ET and at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 at 9:20 a.m. ET, with live and archived webcasts available on the company’s website.
2. Positive Phase 2b Data for Zumilokibart
Recent Phase 2b trial results demonstrated that zumilokibart achieved efficacy on par with leading biologics in atopic dermatitis using only 2–4 annual doses, underscoring its potential to improve patient compliance in the largest inflammatory and immunology market.
3. Blackstone Funding Collaboration
A collaboration with Blackstone secures up to $1.3 billion in non-dilutive funding, removing near-term financing risk and providing capital to advance pivotal trials and support future commercialization of Apogee’s antibody pipeline.
